A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06049329 |
Recruitment Status :
Completed
First Posted : September 22, 2023
Last Update Posted : March 4, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Obesity | Drug: NNC0487-0111 Drug: Placebo (NNC0487-0111) | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 36 participants |
Allocation: | Randomized |
Intervention Model: | Sequential Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Masking Description: | Sponsor staff involved in the clinical trial is masked according to company standard procedures |
Primary Purpose: | Treatment |
Official Title: | Investigation of Safety, Tolerability and Pharmacokinetic Properties of Multiple Doses of Oral NNC0487-0111 in Japanese Participants With Obesity |
Actual Study Start Date : | September 14, 2023 |
Actual Primary Completion Date : | December 15, 2023 |
Actual Study Completion Date : | December 15, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: NNC0487-0111
Once-daily oral administration - 1 of 3 different doses
|
Drug: NNC0487-0111
Participants will get one tablet to swallow at the same time of the day. |
Placebo Comparator: Placebo
Once-daily oral administration - 1 of 3 different doses
|
Drug: Placebo (NNC0487-0111)
Participants will get one tablet to swallow at the same time of the day. |
- Number of treatment emergent adverse events (TEAE) [ Time Frame: From pre-dose on Day 1 until completion of the end of study visit Day 31 ]Number of events
- AUC,MD; the area under the NNC0487-0111 plasma concentration-time curve after last multile dose [ Time Frame: From pre-dose on Day 10 until Day 11 (24 hours post-dose) ]h*nmol/L
- Cmax,MD; the maximum plasma concentration of NNC0487-0111 after last multiple dose [ Time Frame: From pre-dose on Day 10 until completion of the end of study visit Day 31 ]nmol/L
- tmax,MD; the time of maximum plasma concentration of NNC0487-0111 after last multiple dose [ Time Frame: From pre-dose on Day 10 until completion of the end of study visit Day 31 ]hour
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Key inclusion criteria
- Male with both parents of Japanese descent
- Body mass index (BMI) between 25.0 and 34.9 kg/m^2 (both inclusive). Body weight equal to or greater than 65.0 kg
- Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator
Key exclusion criteria
- Any disorder that in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
- Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, or as judged by the investigator
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06049329
Japan | |
Hakata Clinic | |
Fukuoka, Japan, 812-0025 |
Study Director: | Clinical Transparency (dept. 2834) | Novo Nordisk A/S |
Responsible Party: | Novo Nordisk A/S |
ClinicalTrials.gov Identifier: | NCT06049329 |
Other Study ID Numbers: |
NN9487-5022 U1111-1284-5901 ( Other Identifier: World Health Organization (WHO) ) |
First Posted: | September 22, 2023 Key Record Dates |
Last Update Posted: | March 4, 2024 |
Last Verified: | March 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | "According to the Novo Nordisk disclosure commitment on novonordisk-trials.com" |
URL: | http://novonordisk-trials.com |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Obesity Overweight Overnutrition Nutrition Disorders Body Weight |